Cullinan Therapeutics
Update in progressCGEM (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. Its programs include CLN-978 (CD19xCD3) for autoimmune diseases, Velinotamig (BCMAxCD3) for autoimmune diseases, and CLN-049 (FLT3xCD3) for relapsed or refractory AML/MDS, plus Zipalertinib, an EGFR inhibitor for EGFR Exon 20 ins NSCLC in a Phase 2b trial. It licenses Velinotamig, co-develops Zipalertinib, and collaborates with Adimab. Formerly Cullinan Oncology, renamed in 2024. Founded 2016, headquartered in Cambridge, MA.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.27
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Nadim Ahmed M.S.
- Founded2016
- Employees109
- Websitecullinantherapeutics.com
Identifiers
- ISINUS2300311063
- FIGIBBG00HW2DGQ4
- CUSIP230031106
- CIK0001789972